Treatment Decisions for Patients with HCV and CKD


Nancy Reau, MD
Professor of Medicine
Richard B. Capps Chair of Hepatology
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation, Rush University Medical Center, Chicago
Nancy Reau, MD

Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center in Chicago, IL. She received her medical degree from The Ohio State University College of Medicine in Columbus, where she completed a residency and fellowship in gastroenterology/hepatology followed by a second fellowship in advanced transplant hepatology at Johns Hopkins Hospital in Baltimore, MD. Her primary research interests focus on viral hepatitis – from both drug development and a clinical perspective – liver transplantation, and complications of chronic liver disease.

Prof. Reau has been an invited lecturer at numerous presentations focused on viral hepatitis, fatty liver disease, cirrhosis, and liver transplantation. Prof. Reau is a fellow of the American Gastroenterological Association and American Association for the Study of Liver Diseases (AASLD). Additionally, she is the current editor in chief of CLD (Clinical Liver Disease) and was an author of the AASLD/IDSA hepatitis C guidance document. She was the committee chair of the AASLD public policy committee and a member of the AASLD practice guideline committee for four years.

Prof. Reau has authored or coauthored more than 100 peer-reviewed articles that have been published in journals such as Hepatology, Hepatitis Research and Treatment, and Clinics in Liver Disease. She is Co-chair of the National ALF Medical Advisory Committee and sits on multiple advisory boards. She is currently a member of the steering committee for the hepatitis C special interest group (SIG) for the American Association for the Study of Liver Diseases (AASLD) and a member of the ACG training committee.

Anthony Martinez, MD, AAHIVS, FAASLD
Associate Professor of Medicine
Jacobs School of Medicine University at Buffalo
Medical Director, Hepatology Erie County Medical Center Buffalo, NY
Anthony Martinez, MD, AAHIVS, FAASLD
Associate Professor of Medicine

Dr. Martinez cares for patients with liver disease and addiction disorders, including opiate dependency, viral hepatitis, alcoholic and fatty liver disease, at Erie County Medical Center where he is the Medical Director of Hepatology. His clinic “La Bodega” has been recognized both nationally and internationally as a novel co- localized model for the management of viral hepatitis and addiction disorders, and has been awarded a New York State World AIDS Day Commissioner’s Special Recognition Award. The clinic has also been designated as a center for drug user health in New York State. Dr. Martinez has lectured around the world on hepatitis C management among people with substance use disorders, most recently at the International Hepatology Exchange in Amsterdam. His team’s work has been presented at the annual liver meeting of the American Association for the Study of Liver Diseases (AASLD); the annual conference of the International Network On Viral Hepatitis in Substance Users, and at the International Liver Congress.

His research involves improving hepatitis C treatment in populations disproportionately affected by HCV, particularly people who inject drugs. He has been a primary and co-investigator on numerous clinical trials related to new therapeutic agents for hepatitis C and fatty liver disease.

A fierce advocate, he has worked to eliminate hepatitis C treatment restrictions throughout the United States and in Europe.

Dr. Martinez is a member of the AASLD where he was recently elected to the HCV special interest group steering committee, the European Association for the Study of the Liver, and the American Society of Addiction Medicine.

Joseph K. Lim, MD
Professor of Medicine
Director, Clinical Hepatology
Vice-Chief, Section of Digestive Diseases Yale University School of Medicine New Haven, CT
Joseph K. Lim, MD

Dr. Lim is a Professor of Medicine and Vice-Chief of the Section of Digestive Diseases at Yale University, where he serves as Director of Clinical Hepatology and Associate Chief of Yale-New Haven Health System (YNHHS) Digestive Health. He is a graduate of the Feinberg School of Medicine at Northwestern University (Chicago, Illinois, USA), and completed training in Internal Medicine at Yale University (New Haven, Connecticut, USA), and Gastroenterology and Hepatology at Stanford University (Palo Alto, California, USA). In his role at the Yale Liver Center, he conducts patient-oriented research evaluating clinical outcomes in chronic liver disease and runs an active clinical trials program examining novel investigational agents for viral hepatitis and NASH. He has held numerous leadership roles for the AASLD, AGA, and the ACG, and serves as Chair of the EPIC Gastroenterology Specialty Steering Board.

Statement of Need

The low rates of hepatitis C virus (HCV) screening in real-world practice indicate the existence of barriers that need to be overcome. In addition to the COVID-19 pandemic causing delays and/or discontinuations in many hepatitis elimination efforts, there are barriers on the provider level, such as communication challenges, low awareness of HCV, and poor knowledge of HCV screening recommendations. Patient-level barriers include lack of knowledge and awareness of HCV infection, confusion about transmission, and lack of insurance to pay for screening. It is essential that clinicians who treat patients with HCV are aware of these barriers and are equipped with strategies to overcome them in order to ensure screening and optimal management of all populations at risk for HCV infection.

This CMEO BriefCase will introduce a complex HCV case involving a patient with HCV and chronic kidney disease (CKD). Join Drs. Nancy Reau and Anthony Martinez as they dive deeper into treatment and management considerations for such patients, focusing on screening, diagnosis, and risk factors as well as the epidemiology and shared pathobiology of HCV and CKD.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

Implement CDC screening guidelines in practice to improve the detection and diagnosis of HCV.

Financial Support

Supported by an educational grant from Gilead Sciences, Inc.

Target Audience

U.S. and international physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in primary care.

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 1.0

This activity is designated for 1.0 contact hour.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit  from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Note for California Nurses

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.

PAs (AAPA) 1.0

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until the expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.


Through a mutual recognition agreement between the AMA and the UEMS-EACCME®, European physicians completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Credit™ toward their credit requirements. CME Outfitters is based in Radnor, Pennsylvania, USA. Please retain your certificate as proof of completion.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Reau reports the following financial relationships: Consultant: AbbVie Inc.; Gilead Sciences, Inc.; Intercept; and Merck; Grants/Research Support: Genfit; Intercept; and Shire.

Dr. Martinez reports the following financial relationships: Advisory Board: AbbVie Inc.; Antios; Eisai; Gilead Sciences, Inc.; and Intercept Consultant: AbbVie Inc.; Antios; Eisai; Gilead Sciences, Inc.; and Intercept Research Support: AbbVie Inc. and Gilead Sciences, Inc. Speakers Bureau: AbbVie Inc.; Eisai; and Gilead Sciences, Inc.

Dr. Lim (Reviewer/Advisor) reports the following financial relationships: Research Support: Allergan; Celgene Corporation; Eiger BioPharmaceuticals, Inc.; GENFIT; Gilead Sciences, Inc.; Pfizer Inc.; and Viking Therapeutics

Shirley Michelle Franks, MSN, APRN, FNP-BC (peer reviewer)

Kellie Busby, PharmD (planning committee)

Janan Sarwar, PharmD (planning committee)

Susan Perry (planning committee)

Susan H. Yarbrough, CHCP (planning committee)

Sharon Tordoff (planning committee)

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Additional Formats

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.


NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-21-062-H02-P.


Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).



Treatment Decisions for Patients with HCV and CKD
Event Date: 05/05/2022